scholarly journals Establishment and Characterization of High- and Low-lung-metastatic Cell Lines Derived from Murine Colon Adenocarcinoma 26 Tumor Line

1996 ◽  
Vol 87 (1) ◽  
pp. 78-85 ◽  
Author(s):  
Keita Sakata ◽  
Ken-ichi Kozaki ◽  
Ken-ichi Iida ◽  
Rie Tanaka ◽  
Sadako Yamagata ◽  
...  
1993 ◽  
Vol 84 (4) ◽  
pp. 650-655 ◽  
Author(s):  
Mitsuhiro Sato ◽  
Tomotaka Hattori ◽  
Taiji Nishimura ◽  
Masao Akimoto

2002 ◽  
Vol 440 (6) ◽  
pp. 616-626 ◽  
Author(s):  
Jyoji Yamate ◽  
Tomoko Kuriyama ◽  
Maki Kawashima ◽  
Masako Nakanishi ◽  
Mika Ide ◽  
...  

1998 ◽  
Vol 273 (24) ◽  
pp. 15125-15130 ◽  
Author(s):  
Ken-ichi Kozaki ◽  
Osamu Miyaishi ◽  
Osamu Koiwai ◽  
Yoshihiro Yasui ◽  
Akiko Kashiwai ◽  
...  

Cancers ◽  
2021 ◽  
Vol 13 (3) ◽  
pp. 425
Author(s):  
Josep Tarragó-Celada ◽  
Carles Foguet ◽  
Míriam Tarrado-Castellarnau ◽  
Silvia Marin ◽  
Xavier Hernández-Alias ◽  
...  

With most cancer-related deaths resulting from metastasis, the development of new therapeutic approaches against metastatic colorectal cancer (mCRC) is essential to increasing patient survival. The metabolic adaptations that support mCRC remain undefined and their elucidation is crucial to identify potential therapeutic targets. Here, we employed a strategy for the rational identification of targetable metabolic vulnerabilities. This strategy involved first a thorough metabolic characterisation of same-patient-derived cell lines from primary colon adenocarcinoma (SW480), its lymph node metastasis (SW620) and a liver metastatic derivative (SW620-LiM2), and second, using a novel multi-omics integration workflow, identification of metabolic vulnerabilities specific to the metastatic cell lines. We discovered that the metastatic cell lines are selectively vulnerable to the inhibition of cystine import and folate metabolism, two key pathways in redox homeostasis. Specifically, we identified the system xCT and MTHFD1 genes as potential therapeutic targets, both individually and combined, for combating mCRC.


2015 ◽  
Vol 28 (4) ◽  
pp. 464-475 ◽  
Author(s):  
Ikrame Lazar ◽  
Emily Clement ◽  
Manuelle Ducoux-Petit ◽  
Laurence Denat ◽  
Vanessa Soldan ◽  
...  
Keyword(s):  

2014 ◽  
Author(s):  
Naoto Nishimura ◽  
Saishu Yoshida ◽  
Masashi Higuchi ◽  
Hideji Yako ◽  
Hiroki Ueharu ◽  
...  
Keyword(s):  

2018 ◽  
Vol 69 (10) ◽  
pp. 2889-2894
Author(s):  
Ion Virgil Corlan ◽  
Adelina Cheveresan ◽  
Delia Berceanu Vaduva ◽  
Cristian Nica ◽  
Alin Faur ◽  
...  

The present study was aimed to evaluate the confluence percentage of three oral cell lines, namely primary gingival keratinocytes (PGK), primary gingival fibroblasts (HGF) and tongue squamous cell carcinoma (SCC-4). All cells have been monitored at different passages for 21 days. Evaluation of confluence percentage reveals the fact that primary gingival keratinocytes and tongue squamous cell carcinoma at small passages requires a period of about two weeks to reach a confluence of approximately 80% while for the gingival fibroblasts a period of about three times smaller is satisfactory.


2018 ◽  
Vol 18 (8) ◽  
pp. 1184-1196 ◽  
Author(s):  
Abdel-Ghany A. El-Helby ◽  
Helmy Sakr ◽  
Rezk R.A. Ayyad ◽  
Khaled El-Adl ◽  
Mamdouh M. Ali ◽  
...  

Background: Extensive studies were reported in the synthesis of several phthalazine derivatives as promising anticancer agents as potent VEGFR-2 inhibitors. Vatalanib (PTK787) was the first anilinophthalazine published derivative as a potent inhibitor of VEGFR. The discovery of vatalanib as a clinical candidate led to the design and synthesis of different anilinophthalazine derivatives as potent inhibitors for VEGFR-2. The objective of present research work is the synthesis of new agents with the same essential pharmacophoric features of the reported and clinically used VEGFR-2 inhibitors (e.g vatalanib and sorafenib). The main core of our molecular design rationale comprised bioisosteric modification strategies of VEGFR-2 inhibitors at four different positions. </P><P> Material and Methods: A correlation between structure and biological activity of our designed phthalazines was established using molecular docking and VEGFR-2 kinase assay. Results and Discussion: In view of their expected anticancer activity, novel triazolo[3,4-a]phthalazine derivatives 5-6a-o and 3-substituted-bis([1,2,4]triazolo)[3,4-a:4',3'-c]phthalazines 9a-b were designed, synthesized and evaluated for their anti-proliferative activity against two human tumor cell lines HCT-116 human colon adenocarcinoma and MCF-7 breast cancer. It was found that, compound 6o the most potent derivative against both HCT116 and MCF-7 cancer cell lines. Compounds 6o, 6m, 6d and 9b showed the highest anticancer activities against HCT116 human colon adenocarcinoma with IC50 of 7±0.06, 13±0.11, 15±0.14 and 23±0.22 µM respectively while compounds 6o, 6d, 6a and 6n showed the highest anticancer activities against MCF-7 breast cancer with IC50 of 16.98±0.15, 18.2±0.17, 57.54±0.53 and 66.45±0.67 µM respectively. Sorafenib as a highly potent VEGFR-2 inhibitor was used as a reference drug with IC50 of 5.47±0.3 and 7.26±0.3 µM respectively. Nine compounds were further evaluated for their VEGFR-2 inhibitory activity. Compounds 6o, 6m, 6d and 9b emerged as the most active counterparts against VEGFR-2 with IC50 values of 0.1±0.01, 0.15±0.02, 0.28±0.03 and 0.38±0.04 µM, respectively comparable to that of sorafenib (IC50 = 0.1±0.02) µM. Furthermore, molecular docking studies were carried out for all synthesized compounds to investigate their binding pattern and predict their binding affinities towards VEGFR-2 active site. In silico ADMET studies were calculated for the tested compounds. Most of our designed compounds exhibited good ADMET profile. Conclusion: The obtained results showed that, the most active compounds could be useful as a template for future design, optimization, adaptation and investigation to produce more potent and selective VEGFR-2 inhibitors with higher anticancer analogs.


1984 ◽  
Vol 49 (1) ◽  
pp. 162-170 ◽  
Author(s):  
D T Rowe ◽  
P E Branton ◽  
S P Yee ◽  
S Bacchetti ◽  
F L Graham

Sign in / Sign up

Export Citation Format

Share Document